Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) on June 5, 2018. The filing details the outcomes of five specific matters submitted to a vote by security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance and voting results, not a financial statement.
Material Changes and Voting Results
All five matters submitted to a binding vote were approved by stockholders. A total of 4,255,566 shares were entitled to vote, with 3,267,059 shares present or represented by proxy.
- Election of Directors: Six nominees were elected to serve until the 2019 annual meeting. Votes ranged from approximately 1.32 million to 1.37 million "For" each nominee, with significant broker non-votes (1,808,716) recorded.
- Ratification of Auditors: Stockholders ratified BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018 (3,122,294 votes For).
- Long Term Incentive Plan: Approval was granted for the 2012 Plan as amended, including an increase in shares available for issuance (1,255,350 votes For).
- Employee Stock Purchase Plan: Approval was granted to increase the number of shares available for issuance under this plan (1,259,428 votes For).
- Issuance of Common Stock: Stockholders approved the issuance of more than 20% of issued and outstanding common stock to comply with Nasdaq Listing Rule 5635(d) pursuant to a Purchase Agreement with Lincoln Park Capital Fund, LLC dated August 8, 2017 (948,489 votes For).
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on financial performance, or specific risk factors. The primary focus is the successful completion of the annual meeting agenda.
Important Facts for Investor Verification
- Verify the terms of the Purchase Agreement with Lincoln Park Capital Fund, LLC, specifically regarding the issuance of over 20% of outstanding stock.
- Confirm the specific number of shares added to the Long Term Incentive Plan and Employee Stock Purchase Plan following the approved amendments.
- Review the composition of the newly elected Board of Directors to assess governance changes.
- Note the high volume of broker non-votes (1,808,716) on director elections and equity plan proposals, indicating a significant portion of shares held by brokers did not vote on these discretionary matters.